21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. | Am J Clin Oncol;23(3): 258-62, 2000 Jun. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.

Saphner, T; Weller, E A; Tormey, D C; Pandya, K J; Falkson, C I; Stewart, J; Robert, N J.

Affiliation

Saphner T; Green Bay Oncology, Wisconsin 54307-3453, USA. Saphner.Thomas@jimmy.harvard.edu

Am J Clin Oncol ; 23(3): 258-62, 2000 Jun.

Article in En | MEDLINE | ID: mdl-10857889

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Etoposide / Antineoplastic Agents, Phytogenic Type of study: Systematic_reviews Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Am J Clin Oncol Year: 2000 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Etoposide / Antineoplastic Agents, Phytogenic Type of study: Systematic_reviews Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Am J Clin Oncol Year: 2000 Document type: Article Affiliation country: Country of publication: